Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia ...
Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL). Patients were planned to receive a total of 8 cycles of hyper-CVAD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results